Research Paper Volume 16, Issue 10 pp 8998—9022
Breast cancer clinical outcomes and tumor immune microenvironment: cross-dialogue of multiple epigenetic modification profiles
Figure 9. (A, B) The genes with top 10 mutations frequency in the high- and low-risk groups including PIK3CA, TP53, TTN, CDH1, GATA3, MUC16, KMT2C, MAP3K1, HMCN1, and FLG. (C) The ESITIMATE analysis showing that the high-risk scores were linked to a low stromal score while the low-risk scores were highly correlated with a high immune score. (D) The comparison of TMB scores in high and low risk groups. (E) TIDE scores were lower in the high-risk group, suggesting that the high risk score was more responsive to immunotherapy.